| abstract |
The present invention relates to a method of treating chronic fatigue syndrome not associated with an HIV infection. In the method of the present invention patients are administered a pharmaceutically acceptable carrier together with (1) a neuropsychiatrically effective amount of a linear peptide of formula (I): Ra-Ser-Thr-Thr-Thr-Asn-Tyr-R6(I) wherein Ra is Ala, D-Ala or Cys-Ala-, and R6 is Thr, Thr-amide, Thr-Cys or Thr-Cys-amide, or a derivative of the peptide or a physiologically acceptable salt thereof; or (2) a neuropsychiatrically effective amount of a linear peptide of formula (II): R1-R2-R3-R4-R5(II) wherein R1 is X-Y or Y when Y is Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu-, and X is Cys; R2 is Thr-, Ser- or Asp; R3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp; R4 is Tyr; and R5 is Z-X or Z wherein Z is any amino acid and X is Cys, or a derivative of the peptide or a physiologically acceptable salt thereof; or (e) a neuropsychiatrically effective amount of a linear peptide of formula (III): Rx-R2-R3-R4-Ry(III) wherein Rx is Ala-R1, D-Ala-R1 or X-Ala-R1 wherein X, R1, R2, R3, R4 are as defined above, and Ry is Thr-, Thr-amide or Thr-Cys, or a derivative of the peptide or a physiologically acceptable salt thereof. |